ClinicalTrials.gg

Program

imatinib

Also written as “Imatinib”, “imatinib mesylate” and “Imatinib mesylate”.

Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Gastrointestinal Stromal Tumors · Pulmonary Arterial Hypertension · Leukemia, Myeloid, Chronic-Phase · Glioblastoma, led by 8 companies.

Furthest: phase 4, since Apr 26, 200461 company-led studies, 1 open or runningNext primary completion: Aug 30, 2030 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis531 open or runningphase 4since Apr 26, 2004Jul 5, 2000Aug 30, 2030phase 4 · NCT04877522
Exvastat20 open or runningphase 2since Jun 29, 2021Oct 24, 2017none ahead
Amneal Pharmaceuticals10 open or runningphase 3since Apr 1, 2014Apr 1, 2014none ahead
Dong-A ST10 open or runningphase 1since Dec 14, 2012Dec 14, 2012none ahead
HuLow10 open or runningphase 1since Nov 16, 2015Nov 16, 2015none ahead
Nurex S.r.l.10 open or runningphase 2since Jul 2, 2018Jul 2, 2018none ahead
Samyang Biopharmaceuticals10 open or runningphase 1since Dec 27, 2011Dec 27, 2011none ahead
Sino Biopharmaceutical10 open or runningphase 4since Dec 11, 2014Dec 11, 2014none ahead

Also a collaborator on its studies: icon-clinical-research, ppd-development-lp, q2-solutions, parexel and accutest-research-laboratories-i-pvt-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jul 5, 2000.

  1. Nov 6, 2011Phase 1 study in 3rd Line GISTNovartis · NCT01468688 · 60 enrolled · United States, Belgium, Canada and more
  2. Nov 29, 2011Phase 2 study in Gastrointestinal Stromal TumorsNovartis · NCT01483014 · 30 enrolled · Brazil
  3. Dec 27, 2011Samyang Biopharmaceuticals's first study: phase 1 study in HealthyNew to Samyang BiopharmaceuticalsSamyang Biopharmaceuticals · NCT01504984 · 30 enrolled · Korea, Republic of
  4. Nov 28, 2012Phase 4 study in Gastrointestinal Stromal TumorsNovartis · NCT01742299 · 155 enrolled · United States, China, Finland and more
  5. Dec 14, 2012Dong-A ST's first study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Dong-A STDong-A ST · NCT01751919 · 37 enrolled · Korea, Republic of
  6. Jan 17, 2014Phase 3 study in Pulmonary Arterial HypertensionNovartis · NCT02042014 · 8 enrolled · Japan
  7. Apr 1, 2014Amneal Pharmaceuticals's first study: phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT02103322 · 48 enrolled · India
  8. Dec 11, 2014Sino Biopharmaceutical's first study: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT02317159 · 90 enrolled
  9. Nov 16, 2015HuLow's first study: phase 1 study in Malaria, FalciparumNew to HuLowHuLow · NCT02614404 · 15 enrolled · Vietnam
  10. Oct 24, 2017Exvastat's first study: phase 1 study in Acute Lung InjuryNew to ExvastatExvastat · NCT03328117 · 47 enrolled · United Kingdom
  11. Jun 15, 2018Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT03578367 · 104 enrolled · United States, Austria, Canada and more
  12. Jul 2, 2018Nurex S.r.l.'s first study: phase 2 study in Malaria, FalciparumNew to Nurex S.r.l.Nurex S.r.l. · NCT03697668 · 50 enrolled · Vietnam
  13. May 4, 2021Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT04877522 · 347 planned · United States, Argentina, Austria and more
  14. Jun 29, 2021Phase 2 study in Respiratory Distress SyndromeExvastat · NCT04953052 · India

Ahead

  1. Aug 30, 2030Primary completion: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT04877522

TargetBeta

“Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 61 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT04953052Respiratory Distress Syndrome · India2WithdrawnExvastatAug 31, 20220
NCT04877522Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more4RecruitingNovartisAug 30, 2030347
NCT03697668Malaria, Falciparum · Vietnam2UNKNOWNNurex S.r.l.Dec 31, 201850
NCT03578367Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Austria, Canada and more2CompletedNovartisNov 8, 2021104
NCT03328117Acute Lung Injury · United Kingdom1CompletedExvastatMar 5, 201847
NCT02614404Malaria, Falciparum · Vietnam1CompletedHuLowDec 2, 201615
NCT02317159Leukemia, Myelogenous, Chronic, BCR-ABL Positive4UNKNOWNSino BiopharmaceuticalJun 201790
NCT02103322Leukemia, Myelogenous, Chronic, BCR-ABL Positive · India3CompletedAmneal PharmaceuticalsMar 201448
NCT02042014Pulmonary Arterial Hypertension · Japan3CompletedNovartisOct 17, 20168
NCT01751919Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Korea, Republic of1CompletedDong-A STAug 201237
NCT01742299Gastrointestinal Stromal Tumors · United States, China, Finland and more4CompletedNovartisApr 20, 2026155
NCT01504984Healthy · Korea, Republic of1CompletedSamyang BiopharmaceuticalsApr 201230
NCT01483014Gastrointestinal Stromal Tumors · Brazil2CompletedNovartisJan 201230
NCT014686883rd Line GIST · United States, Belgium, Canada and more1CompletedNovartisJul 29, 201660
NCT01392495Pulmonary Arterial Hypertension · United States, Australia, Belgium and more3TerminatedNovartisMar 201417
NCT01392469Pulmonary Arterial Hypertension · United States, Australia, Belgium and more3CompletedNovartisOct 25, 201221
NCT01316458Prostatic Neoplasms · Germany2CompletedNovartisJul 201051
NCT01271166Neoplasms · Australia1TerminatedNovartisAug 200910
NCT01216085CML · Korea, Republic of2CompletedNovartisJul 201110
NCT01172548Gastrointestinal Stromal Tumors · Algeria, Egypt, India and more2CompletedNovartisMar 2014132
NCT01117987Pulmonary Arterial Hypertension · United States, Austria, Belgium and more3TerminatedNovartisApr 2014144
NCT01066468Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Russian Federation1TerminatedNovartisMay 20113
NCT00940563Advanced Gastrointestinal Stromal Tumors · Italy2CompletedNovartisAug 2004135
NCT00902174Pulmonary Arterial Hypertension · United States, Austria, Belgium and more3CompletedNovartisMay 2011202
NCT00867113Gastrointestinal Stromal Tumors · United States2CompletedNovartisDec 20, 201691
NCT00613171Scleroderma, Systemic · United States, Germany, Italy and more2CompletedNovartisJan 13, 201027
NCT00510354Progressive Gastrointestinal Stromal Tumor · Germany4CompletedNovartisNov 201228
NCT00477269Pulmonary Arterial Hypertension · United States, Austria, Germany and more3CompletedNovartisJan 201459
NCT00471497Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more3CompletedNovartisSep 2, 2009846
NCT00441155Gastrointestinal Stromal Tumors · United States, France, Italy1CompletedNovartisJan 201114
NCT00428909Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Korea, Republic of1CompletedNovartisAug 200812
NCT00427583Neurofibrosarcoma · Germany3TerminatedNovartisApr 200911
NCT00426179Rhinitis, Allergic, Seasonal · United Kingdom2CompletedNovartis30
NCT00422825Leukemia, Myelogenous, Chronic, BCR-ABL Positive1CompletedNovartisSep 200616
NCT00420043Leukemia, Myelogenous, Chronic, BCR-ABL Positive1CompletedNovartisNov 200632
NCT00417807Refractory Desmoplastic Small Round Cell Tumors · Italy2CompletedNovartisJun 20099
NCT00372476Breast Neoplasms · Germany4CompletedNovartisJul 201233
NCT00333840Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more3CompletedNovartisMar 20121,106
NCT00290771Glioblastoma · United States2TerminatedNovartisAug 2008231
NCT00237185Gastrointestinal Stromal Tumors · United States, Australia, Finland2CompletedNovartisJun 2013148
NCT00237172Gastrointestinal Stromal Tumors2CompletedNovartisJul 200572
NCT00237120Leukemia, Myelogenous, Chronic, BCR-ABL Positive3CompletedNovartis100
NCT00171977Gastrointestinal Stromal Tumors · Japan4CompletedNovartisApr 200964
NCT00171938Glioblastoma · Brazil2TerminatedNovartisJun 200630
NCT00171912Hypereosinophilic Syndrome · Australia2CompletedNovartisJan 201238
NCT00171899Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Canada4CompletedNovartisJun 200780
NCT00171860Hypereosinophilic Syndrome · Belgium2TerminatedNovartisJul 200724
NCT00171249Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, France, Germany and more2CompletedNovartisSep 23, 2013293
NCT00171223Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, France, Germany and more2CompletedNovartisNov 29, 2013532
NCT00171158Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, France, Germany and more2CompletedNovartisApr 2013260
NCT00154388Adenocarcinoma2CompletedNovartisJan 2007185
NCT00154375Glioblastoma · Germany3CompletedNovartisAug 2008240
NCT00154349Philadelphia Chromosome Positive Acute Lymphocytic Leukemia2CompletedNovartisFeb 20078
NCT00154336Arthritis, Rheumatoid · Austria, Canada, Finland and more2CompletedNovartisAug 200550
NCT00150072Chordoma · Italy, Switzerland2CompletedNovartisApr 200855
NCT00124748Leukemia, Myeloid, Chronic-Phase · United States, Argentina, Australia and more3TerminatedNovartisNov 2010476
NCT00093639Leukemia · United States2CompletedNovartisAug 2006
NCT00081926Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States4CompletedNovartis112
NCT00006475Leukemia · United States2CompletedNovartisDec 2002
NCT00006053Leukemia · United States2CompletedNovartisMar 2003

How it is read

Names in the registry

  • “Imatinib”, 18 entries
  • “imatinib mesylate”, 15 entries
  • “Imatinib mesylate”, 6 entries
  • “Imatinib Mesylate”, 5 entries
  • “imatinib”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.